Nanotechnology Now







Heifer International

Wikipedia Affiliate Button


DHgate

Home > Press > Celator(R) Pharmaceuticals Selected to Participate in NCI's Nanotechnology Characterization Laboratory Assay Cascade for Characterization of Nanoparticle Prodrug Delivery Platform

Abstract:
Celator Pharmaceuticals today announced that the National Cancer Institute's (NCI) Nanotechnology Characterization Laboratory (NCL), operated by SAIC-Frederick (Frederick, Maryland), has agreed to conduct characterization studies to advance the development of the company's nanoparticle drug formulation technology.

Celator(R) Pharmaceuticals Selected to Participate in NCI's Nanotechnology Characterization Laboratory Assay Cascade for Characterization of Nanoparticle Prodrug Delivery Platform

Princeton, NJ | Posted on February 17th, 2010

The agreement is part of the NCI's Advanced Technology Partnerships Initiative, which aims to accelerate the delivery of new products to cancer patients through the strategic application of advanced technologies and effective translational research partnerships.

The current material transfer agreement focuses on Celator's hydrophobic docetaxel prodrug nanoparticle (HDPN) formulation to support an eventual investigational new drug (IND) filing with the U.S. Food and Drug Administration. Specifically, the NCL has selected HDPN for intensive physical characterization, in-vitro studies, and in-vivo pharmacology and toxicology protocols.

HDPN is the result of collaboration with Princeton University and subsequent discovery and research efforts at Celator. The technology belongs to a proprietary nanoparticle prodrug delivery platform with broad potential applicability in cancer and other diseases. Docetaxel is a type of taxane drug that is widely used to treat a range of cancers including lung, breast, and prostate.

Celator scientists have demonstrated the HDPN formulation substantially increases drug circulation lifetime and efficacy compared to conventional docetaxel formulations. These improvements formed the basis of the decision made by the NCL's scientific review committee for the characterization study of HDPN.

"Our approach to delivering taxanes such as docetaxel differs from most in that we make the drug more hydrophobic thereby allowing the nanoparticle-incorporated prodrug to circulate in the blood for days after injection," said Dr. Lawrence Mayer, president and head of research of Celator Pharmaceuticals. "Our studies have shown that keeping the drug circulating for extended times correlates with the ability to induce regression of solid tumors to below detectable limits."

"We are pleased the NCL is conducting this work to help us advance HDPN toward the clinic," said Scott Jackson, chief executive officer of Celator Pharmaceuticals. "The technology has broad potential application in addressing therapeutic needs and HDPN represents our first approach."

####

About Celator Pharmaceuticals
Celator Pharmaceuticals, Inc., with locations in Princeton, NJ, and Vancouver, BC, is a privately held pharmaceutical company developing new and more effective therapies to treat cancer. CombiPlex®, the company's proprietary drug ratio technology platform, represents a novel approach that identifies molar ratios of drugs that will deliver a synergistic benefit, and locks the desired ratio in a nano-scale drug delivery vehicle that maintains the ratio in patients with the goal of improving clinical outcomes. The company pipeline includes two Phase 2 products; CPX-351 (a liposomal formulation of cytarabine:daunorubicin) for the treatment of acute myeloid leukemia and CPX-1 (a liposomal formulation of irinotecan:floxuridine) for the treatment of colorectal cancer; a preclinical stage compound, CPX-571 (a liposomal formulation of irinotecan:cisplatin); and multiple research programs, including the hydrophobic docetaxel prodrug nanoparticle (HDPN) formulation. Based on the applications of CombiPlex and the proprietary nanoparticle prodrug delivery platform, Celator is positioned to advance a broad pipeline of cancer therapies involving both previously approved and novel drug agents.

For more information, please visit the company's website at www.celatorpharma.com.

Information on ongoing trials is available at www.clinicaltrials.gov.

For more information, please click here

Contacts:
Celator Pharmaceuticals, Inc.
303B College Road East
Princeton, NJ 08540
USA
Telephone: (609) 243-0123
Fax: (609) 243-0202

Celator Pharmaceuticals Corp.
1779 West 75th Avenue
Vancouver, BC V6P 6P2
Canada
Telephone: (604) 708-5858
Toll-free: (866) 708-5858
Fax: (604) 708-5883

Copyright © PrNewswire

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

New ASTM Standards Will Help Educate Present and Future Nanotechnology Workforces April 26th, 2015

Heat makes electrons’ spin in magnetic superconductors April 26th, 2015

QD Vision Wins 2015 Bronze Edison Award for Color IQ™ Quantum Dot Technology April 26th, 2015

SEFCU, SUNY Poly CNSE Announce Winning Student-Led Teams in the 6th Annual $500,000 New York Business Plan Competition April 25th, 2015

Nanomedicine

Northwestern scientists develop first liquid nanolaser: Technology could lead to new way of doing 'lab on a chip' medical diagnostics April 25th, 2015

Nanotech-enabled moisturizer speeds healing of diabetic skin wounds: Spherical nucleic acids silence gene that interferes with wound healing April 24th, 2015

Fast and accurate 3-D imaging technique to track optically trapped particles April 24th, 2015

A silver lining: UCSB researchers cradle silver nanoclusters inside synthetic DNA to create a programmed, tunable fluorescent array April 23rd, 2015

Announcements

New ASTM Standards Will Help Educate Present and Future Nanotechnology Workforces April 26th, 2015

Heat makes electrons’ spin in magnetic superconductors April 26th, 2015

QD Vision Wins 2015 Bronze Edison Award for Color IQ™ Quantum Dot Technology April 26th, 2015

SEFCU, SUNY Poly CNSE Announce Winning Student-Led Teams in the 6th Annual $500,000 New York Business Plan Competition April 25th, 2015

Nanobiotechnology

A silver lining: UCSB researchers cradle silver nanoclusters inside synthetic DNA to create a programmed, tunable fluorescent array April 23rd, 2015

Scientists Use Nanoscale Building Blocks and DNA 'Glue' to Shape 3D Superlattices: New approach to designing ordered composite materials for possible energy applications April 23rd, 2015

UCLA nanoscientists are first to model atomic structures of three bacterial nanomachines: Cryo electron microscope enables scientists to explore the frontiers of targeted antibiotics April 21st, 2015

Rafts on the cell membrane: Researchers from TU Wien (Vienna) shed light on a big secret of cell membranes: The 'lipid rafts', which have been believed to move within the cell membrane, do not really exist April 21st, 2015

Alliances/Partnerships/Distributorships

How can you see an atom? (video) April 10th, 2015

FibeRio and VF Corporation Form Strategic Partnership to Lead the Apparel and Footwear Markets in Nanofiber Technology April 8th, 2015

UK National Graphene Institute Selects Bruker as Official Partner: World-Leading Graphene Research Facility Purchases Multiple Bruker AFMs April 7th, 2015

NXP and GLOBALFOUNDRIES Announce Production of 40nm Embedded Non-Volatile Memory Technology: Co-developed technology to leverage GLOBALFOUNDRIES 40nm process technology platform March 24th, 2015

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More










ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project